Abstract
This review examines some of the kinase inhibitors as cancer treatments, their
targets, how they work or sometimes fail to work and what researchers have
learned from the first few years of targeted cancer therapeutics.
Cell Notes 16, 26–29.
Kari Kenefick
Promega Corporation
2006